Sanofi $SNY Shares Acquired by Probity Advisors Inc.

Probity Advisors Inc. lifted its position in shares of Sanofi (NASDAQ:SNY) by 14.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,846 shares of the company’s stock after purchasing an additional 2,599 shares during the period. Probity Advisors Inc.’s holdings in Sanofi were worth $1,007,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its position in shares of Sanofi by 1.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 11,036,878 shares of the company’s stock worth $612,106,000 after purchasing an additional 193,196 shares in the last quarter. Federated Hermes Inc. increased its position in shares of Sanofi by 58.5% during the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock worth $218,933,000 after purchasing an additional 1,456,269 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Sanofi by 6.9% during the first quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company’s stock worth $181,764,000 after purchasing an additional 211,641 shares in the last quarter. Raymond James Financial Inc. increased its position in shares of Sanofi by 15.1% during the first quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock worth $179,914,000 after purchasing an additional 425,597 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Sanofi during the first quarter worth about $177,831,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on SNY. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a report on Wednesday, October 8th. Barclays reissued an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Finally, Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $62.67.

Sanofi Price Performance

Shares of SNY opened at $49.73 on Tuesday. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The stock’s 50 day moving average is $48.54 and its two-hundred day moving average is $49.55. The firm has a market capitalization of $122.11 billion, a PE ratio of 11.95, a P/E/G ratio of 1.23 and a beta of 0.51. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion during the quarter, compared to analysts’ expectations of $9.91 billion. During the same period in the prior year, the firm posted $1.73 EPS. Sanofi’s revenue for the quarter was down 7.0% compared to the same quarter last year. Research analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.